PharmaShots | Incisive News in 3 Shots

Subscribe Now

fourth indication

Novartis' Cosentyx (secukinumab) Receives EC's Approval for Axial Spondyloarthritis Spectrum Marking its Fourth Indication in EU

Novartis' Cosentyx (secukinumab) Receives EC's Approval for Axial Spondyloarthritis Spectrum Marking its Fourth Indication in EU

April 29, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us